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RESEARCH ARTICLE Open Access
The effect of antenatal depression and
antidepressant treatment on placental
tissue: a protein-validated gene expression
study
Åsa Edvinsson1* , Charlotte Hellgren1, Theodora Kunovac Kallak1, Helena Åkerud2, Alkistis Skalkidou1,
Elisabet Stener-Victorin3, Romina Fornes3, Olav Spigset4,5, Susanne Lager1, Jocelien Olivier6† and
Inger Sundström-Poromaa1†
Abstract
Background: Antenatal depression affects 10–20% of pregnant women. Around 2–4% of European pregnant women
use antidepressant treatment, most commonly selective serotonin reuptake inhibitors (SSRIs). Poor pregnancy
outcomes, such as preterm birth and low birth weight, have been described in women with antenatal depression and
in pregnant women on SSRI treatment. However, the effects of antenatal depression and antidepressant treatment on
the placenta are largely unknown. The aim of this work was to compare placental gene and protein expression in
healthy women, women with untreated antenatal depression and women on antidepressant treatment during
pregnancy.
Methods: Placental samples from 47 controls, 25 depressed and 45 SSRI-treated women were analysed by means of
qPCR using custom-designed TaqMan low-density arrays (TLDAs) for 44 genes previously known to be involved in the
pathophysiology of depression, and expressed in the placenta. Moreover, placental protein expression was determined
by means of immunohistochemistry in 37 healthy controls, 13 women with untreated depression and 21 women on
antidepressant treatment. Statistical comparisons between groups were performed by one-way ANOVA or the Kruskal–
Wallis test.
Results: Nominally significant findings were noted for HTR1A and NPY2R, where women with untreated depression
displayed higher gene expression than healthy controls (p < 0.05), whereas women on antidepressant treatment had
similar expression as healthy controls. The protein expression analyses revealed higher expression of HTR1A in
placentas from women on antidepressant treatment, than in placentas from healthy controls (p < 0.05).
Conclusion: The differentially expressed HTR1A, both at the gene and the protein level that was revealed in this study,
suggests the involvement of HTR1A in the effect of antenatal depression on biological mechanisms in the placenta.
More research is needed to elucidate the role of depression and antidepressant treatment on the placenta, and,
further, the effect on the fetus.
Keywords: Antenatal depression, Antidepressant treatment, Selective serotonin reuptake inhibitors, Placental gene
expression, TaqMan low-density array, Placental protein expression, Immunohistochemistry
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Introduction
During pregnancy a woman’s body undergoes numer-
ous changes, both physically and mentally. The overall
risk of experiencing depressive symptoms during this
time period is as common as in the population as a
whole, approximately 10–20% [1, 2], whereas major de-
pressive disorder is found in around 4–7% of pregnant
women [3–6]. Suffering from depression in pregnancy
could have serious consequences for both the mother
and the child. Almost 11% of women of childbearing
age in Sweden were using antidepressant medication in
2016 [7]. The most commonly prescribed antidepres-
sants in pregnancy are selective serotonin reuptake in-
hibitors (SSRIs), with a prevalence of around 2–4% in
pregnant women in Europe, and 4–10% in North
America [8–12]. Poor pregnancy outcomes, such as
preterm birth and low birth weight have been reported
both in women with antenatal depression and in
women who used antidepressant treatment during
pregnancy, and it is presently unclear whether it is the
SSRI treatment or the depression itself that causes
these complications [13–15].
The placenta is a transitory organ that connects the
fetus to the mother and acts as a bridge between the
maternal and the fetal circulations. The fetal part of the
placenta consists of chorionic villous trees that contain
a variable amount of fetal vessels and stroma covered
by a cytotrophoblast and a syncytiotrophoblast layer.
Maternal blood pools into the intervillous space and
bathes the villous trees, where feto-maternal exchange
takes place [16]. Anchoring villi are attached to the ma-
ternal part of the placental tissue, the decidua basalis,
which is developed from uterine tissue. Placental dys-
function can have devastating consequences for both
the mother and the child. Fetal growth can be nega-
tively affected if the placental blood supply is insuffi-
cient or if the transport of oxygen and nutrients is
affected, which can lead to low birth weight, preterm
birth, and birth defects [17–19]. Moreover, the mother
is at increased risk of developing conditions such as
pre-eclampsia as a result of placental dysfunction, and a
history of pre-eclampsia is also associated with abnor-
malities in the placenta in the current pregnancy [20].
SSRIs have the ability to cross the placenta and have
been found in both cord blood and amniotic fluid [21,
22]. Serotonin is involved in embryogenesis [23], pla-
centation [24], and placental vasoconstriction [25], all
of which may affect the fetus. In mice, maternal SSRI
treatment has been shown to alter multidrug resist-
ance (phosphoglycoprotein) activity both in the pla-
centa and in the fetal and maternal blood-brain
barrier, resulting in altered drug transfer into the fetal
and maternal brain [26]. Another study in mice re-
vealed a placental serotonin synthetic pathway [27],
where serotonin produced in the placenta accumulates
in the fetal forebrain during the developmental phase
that corresponds to the first and second trimester in
humans. This phase includes cortical neurogenesis,
migration and initial axon targeting, which are crucial
mechanisms for normal neurodevelopment [27].
Regarding the effect of maternal mental illness on pla-
cental function, several studies within a review by Gen-
tile and Fusco describe altered gene/protein expression
and epigenetic modifications in placenta from depressed
mother with or without antidepressant treatment [28].
In addition, studies carried out by our research group
have revealed altered gene expression in the fetal part of
the placenta in women with depression during preg-
nancy compared with non-depressed pregnant women
[29, 30]. Moreover, use of SSRIs during pregnancy has
been found to alter placental gene expression in the fetal
part compared with placental gene expression in healthy
pregnancy [29, 30]. Oxytocin has an important endo-
crine role in pregnancy and parturition and methylation
of the oxytocin receptor (OXTR) has been linked to
mental disorders [31, 32]. Of interest is a study by Galb-
ally et al. suggesting that antidepressant exposure rather
than depressive symptoms during pregnancy can alter
OXTR methylation in placental tissue [33]. Also, de-
creased expression of the imprinted gene PEG3 in the
placenta have been found associated with maternal de-
pression [34]. Investigators have also described genes in-
volved in the hypothalamic–pituitary–adrenal (HPA)
axis that are differentially expressed in placentas from
mothers suffering from prenatal stress compared with
healthy mothers [35–39]. There are also studies describ-
ing associations between maternal depression, the pla-
centa and child behaviour and temperament [40, 41].
However, much remains to be revealed concerning the
biological effects of fetal exposure to maternal depres-
sion and its treatment. Specifically, more research is
needed to elucidate the different effects of antenatal de-
pression and antidepressant treatment on placental func-
tion and the offspring. The aim of this work was to
compare placental gene and protein expression in
healthy women, women with antenatal depression and
women on antidepressant treatment during pregnancy.
For this purpose, we selected genes that have previously
been shown to be involved in mood disorders, and at
the same time known to be expressed in the placenta.
Materials and methods
Study population
The placental samples for this study were derived from
the Biology, Affect, Stress, Imaging, Cognition (BASIC)
project, which is a population-based, longitudinal study
on psychological well-being during pregnancy and the
postpartum period, conducted at the Department of
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Obstetrics and Gynaecology, Uppsala University Hos-
pital. In the BASIC study all women attending routine
ultrasound examination at gestational weeks 16–18 are
invited to participate. Exclusion criteria in the BASIC
project are (1) inability to communicate adequately in
Swedish, (2) protected identity, (3) age less than 18 years,
and (4) blood-borne infectious diseases. In Uppsala, all
routine ultrasound examinations are performed at Upp-
sala University Hospital and 97% of pregnant women
participate. Moreover, the only delivery ward in the
county is at Uppsala University Hospital, thus forming
the basis of a population-derived sample. Written in-
formed consent is obtained from women who choose to
participate in the BASIC project, and within this consent
document women also specify whether or not blood and
placental samples may be collected at delivery. Placental
tissue was collected between April 2010 and September
2013, and in all, 957 placental samples were collected.
In the BASIC project, women are followed by means
of web-based questionnaires at gestational weeks 17 and
32. At both of these times women fill out the Edinburgh
Postnatal Depression Scale (EPDS) [42, 43], together
with detailed information on previous and ongoing med-
ical treatment, including antidepressant use, smoking,
educational level and country of origin. Information on
maternal body mass index (BMI) (gestational weeks 10–
12), obstetric and perinatal variables is retrieved from
the medical records.
The EPDS is a self-administered instrument that con-
tains 10 statements, scored from zero to three, rendering
a maximum score of 30. This instrument does not pro-
vide a diagnosis of depression as such, but a higher total
score increases the likelihood of having a major depres-
sive episode. EPDS statements are based on the past
seven days. The sensitivity is relatively low, but the scale
has a specificity of 98–99% for major depression at a
cut-off score of > 12 points during pregnancy [44]. The
internal consistency and test-retest reliability of the
EPDS questionnaires had a Cronbach’s alpha of 0.88,
and a coefficient of stability of 0.77.
A selection of the women in the BASIC cohort also
participated in a psychophysiological sub-study in late
pregnancy and early postpartum. As part of this sub-
study, women were subjected to a psychiatric interview,
the Mini International Neuropsychiatric Interview
(MINI), by which a diagnosis of minor or major depres-
sive disorder was established. Blood samples were also
drawn at these visits.
For this study, placental samples from 47 healthy con-
trols, 25 women with untreated antenatal depression and
45 women on antidepressant treatment were used. Gen-
eral exclusion criteria for all groups were maternal age >
42 years, alcohol use during pregnancy, any pregnancy
complication that would influence, or be a sign of,
compromised placental function such as pre-eclampsia,
gestational diabetes, pre-pregnancy diabetes, intrauterine
growth restriction, offspring born small for gestational
age, and gestational age < 35 weeks at delivery.
The definition of being depressed in this study was a
diagnosis of depression according to the MINI inter-
view (n = 19), or an EPDS score of ≥ 12 in weeks 17 and
32, together with a diagnosis of previous major depres-
sion according to MINI or according to medical re-
cords (n = 6). According to the medical records women
on antidepressants used their treatment during at least
half of the pregnancy in clinically relevant doses. The
control subjects had a maximum EPDS score of 11, and
no on-going/earlier psychiatric disease according to
medical records, and were matched to the depressed
and SSRI-treated women with respect to BMI (± 2.0 kg/
m2) and age (± 5 years).
Samples
The BASIC placental tissue samples were collected and
processed directly after delivery. Two basal-plate biopsy
samples from the maternal-fetal interface, of approxi-
mately one cm in thickness, were excised from the cen-
tral part of the placenta containing both the maternal
decidua basalis and fetal villous tissue. Calcified areas or
infarcts in the tissue were avoided. The tissue samples
were carefully rinsed with sterile phosphate-buffered sa-
line (PBS) and put on dry ice within 30 min after deliv-
ery. The samples were stored at − 70 °C until further
processing. For paraffin-embedded placental samples,
tissues were fixed for 24 h in 4% formalin, and stored in
70% ethanol until paraffin-embedding.
A placental sample of 3 mm3 was taken from the
fetal side of the frozen placental tissue piece for isola-
tion of total RNA using RNeasy mini kits (#74106,
Qiagen, Hilden, Germany). The tissue was homoge-
nized and lysed using a rotor-stator homogenizer and
RLT-β-mercaptoethanol, according to the manufac-
turer’s protocol. The amount and quality of RNA
were determined by using NanoDrop technology and
by Agilent RNA 6000 Nano assays, respectively (Dal-
cochromtech, Life Technologies Inc., CA, USA).
Single-strand cDNA was synthesized from 250 ng of
total RNA using Superscript VILO MasterMix kits (Life
Technologies, Paisley, UK), following the manufacturer’s
protocol, resulting in a total amount of 250 ng cDNA/
sample.
Low-density Array analysis
Quantitative real-time PCRs were run with custom-
designed TaqMan low-density arrays (TLDAs) (Applied
Biosystems, Foster city, CA, USA) for 44 genes previ-
ously known to be involved in the pathophysiology of
depression, and expressed in the placenta
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(Additional file 1). These genes represent: i) monoamin-
ergic pathways, including genes such as sodium-
dependent serotonin transporter (SLC6A4), aromatic l-
amino acid decarboxylase (AADC), and monoamine oxi-
dase A (MAOA), all involved in monoamine transport to
the fetus [27, 45]; ii) hypothalamic–pituitary–adrenal
(HPA) axis function, including genes such as
corticotrophin-releasing hormone (CRH) and neuropep-
tide Y (NPY), which drive the maternal HPA axis during
pregnancy [46], and 11β hydroxysteroid dehydrogenase
types 1 and 2 (HSD11B1 and 2), responsible for shuttling
of cortisol to the fetus [47]; iii) other hormonal systems,
including oxytocin (OXT) and enzymes involved in pro-
gesterone metabolism, such as 5α-reductase types I and
II (SRD5A1 and 2) and 3α-hydroxysteroid dehydrogen-
ase (AKR1C4) [48, 49]; iv) growth factors, including vas-
cular endothelial growth factor (VEGF) and brain-
derived neurotrophic factor (BDNF), and v) genes in-
volved in placental drug metabolism and transport. Fi-
nally, we included nerve growth factor (NGF) to validate
our previous findings [29, 30]. Four genes, GAPDH,
TOP1, YWHAZ, and ABCB1 were included in the arrays
as reference genes (Additional file 1).
Each TaqMan LDA consisted of 384 wells and 8 ports
(48 wells/assays per port). The 117 samples were loaded
to the TLDAs via the ports, one sample per port, which
resulted in 15 TLDAs in total. Samples were run as single-
tons, and the amount of cDNA in each loading port was
equivalent to 100 ng of mRNA. The arrays were run ac-
cording to the manufacturer’s protocol with an ABI Prism
7900HT Sequence Detection System and ABI Prism
7900HT SDS software version 2.4 (Applied Biosystems).
Each assay included a forward primer, a reverse pri-
mer, and a TaqMan® MGB probe (Additional file 1) with
the reporter FAM™ and the quencher MGB-NFQ. Nega-
tive controls consisted of no template (water).
Each placental sample (100 ng cDNA) was diluted with
sterile water to a volume of 50 μL, with addition of an
equal volume of TaqMan Universal PCR Master Mix
(2 ×; Applied Biosystems). The sample was loaded to the
TaqMan LDA, which was then centrifuged twice for 1
min at 331×g. In cases of excess sample in the fill reser-
voir the LDAs were spun for an additional 1 min. The
final volume in each well after centrifugation was 1.5 μL,
which yielded 1.5 ng cDNA per reaction. Real-time RT-
PCRs were run with thermal cycling conditions of 2 min
at 50 °C, 10 min at 95 °C, followed by 40 cycles of de-
naturation at 95 °C for 15 s and annealing and extension
at 60 °C for 1 min.
Analysis of real-time RT-PCR data
Manual confirmation of threshold detection was con-
ducted for quality-control purposes. We utilized Ct
number as input for our variability analysis among tissue
samples for each target. Results for each target in TLDA
analysis were quantified concurrently using the same
baseline and threshold for a target gene in order to limit
inter-plate errors in the analysis. By using NormFinder,
GeNorm algorithms and GenEx software (MultiD
Analyses) [50], we identified GAPDH and YWHAZ as
the most stable combination of genes to use for
normalization in data analysis. Normalization of the data
included subtraction of the mean Ct values of the best
combination of housekeeping genes from the mean Ct
value for each gene in each group (ΔCt). A higher ΔCt
value refers to a lower gene expression, and a lower ΔCt
value refers to a higher gene expression respectively.
Immunohistochemistry
Based on availability of paraffin-embedded blocks of
placental tissue among women included in the gene-
expression analysis, placental-protein expression was
determined in 37 healthy controls, 13 women with un-
treated depression and 21 women on antidepressant
treatment. The paraffin-embedded blocks were sec-
tioned (4 μm) and the samples placed on Superfrost
slides. The slides were processed according to a stan-
dardized immunohistochemistry protocol, with anti-
body retrieval in 1 × citrate buffer for 10 min in a 650
W microwave oven. An endogenous peroxide-blocking
step for 10 min in 3% H2O2 in ethanol was followed by
a non-immune block with 5% normal goat/horse serum
in 0.1% bovine serum albumin (BSA) in PBS for one
hour at room temperature (RT).
The primary antibodies used in the following step
were anti-HTR1A (PA5–28090, rabbit, Thermo Fisher
Scientific) and anti-NPY2R (PA1–41576, rabbit, Thermo
Fisher Scientific), at dilutions of 1:500 and 1:250, re-
spectively. The antibodies were applied to the slides,
which were then kept at 5 °C overnight. As a negative
control we used 0.1% BSA in PBS. After the primary
antibody step a secondary antibody was applied to the
tissue sections for one hour at RT at a dilution of 1:300
in 0.1% BSA in PBS. The secondary antibody used in this
study was a biotinylated Goat Anti-Rabbit antibody
(Vector labs BA-1000). As a detection method we used a
colorimetric system including an enzyme, horseradish
peroxidase (HRP) (dilution 1:400, 1 h at RT, Vector labs
A-2004), and a substrate, DAB (3,3′-diaminobenzidine)
(dilution, chromogen/substrate 1:50, 20 s at RT) (Dako).
The enzyme HRP catalyses oxidation of the substrate
DAB, resulting in a brown colour in the sample. Mayer’s
haematoxylin was applied for staining of the cell nuclei.
Immunohistochemical scoring
The immunohistochemically stained placental-tissue sec-
tions were analysed in terms of staining pattern, distri-
bution, intensity (0–3), and the proportion (%) of stained
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cells. Two independent scorers carried out the scoring
in a blinded manner as regards case/control status. In-
tensity was defined as negative (0), weak (1), medium
(2), or strong (3). The tissue samples were further evalu-
ated by calculating an H-score (histo-score), based on
the staining intensity and proportion of stained cells.
The H-score takes into account different staining inten-
sities within the same tissue sample, and is assigned
using the following formula: [1 × (% of cells with inten-
sity score 1) + 2 × (% of cells with intensity score 2) +
3 × (% of cells with intensity score 3)]. The final score
thus ranges from 0 to 300 [51, 52].
Antidepressant concentration measurement
Maternal blood for the analysis of antidepressant serum
concentrations was obtained at the delivery ward prior
to the woman’s delivery. Blood samples were centrifuged
at 1500 RCF for 10 min and the sera were stored at −
70 °C within 1 h of delivery.
Citalopram, escitalopram, sertraline, and fluoxetine
and its active metabolite norfluoxetine were analysed
using liquid chromatography–mass spectrometry by
methods described previously [53]. In brief, citalopram
and escitalopram were extracted from serum by liquid–
liquid extraction using a mixture of hexane/butanol/
acetonitrile (93/5/2) as extraction solvent. Sertraline,
fluoxetine and norfluoxetine were extracted from
serum by liquid–liquid extraction using butyl chloride
as extraction solvent. All analytes were then quanti-
fied on an Agilent MSD 1100 LC-MS system (Agilent
Technologies, Palo Alto, CA, USA) after separation
on C18 columns, and subsequent detection as pseudo-
molecular (M + 1) ions. Internal standards were used.
Together with the unknown patient samples, each
analytical series contained seven calibrators covering
therapeutic, subtherapeutic, and toxic concentrations.
In addition, six quality-control samples with represen-
tative target concentrations were included. The limits
of quantification were 5 nmol/L for sertraline and 10
nmol/L for citalopram, escitalopram, fluoxetine and
norfluoxetine. Accuracy was controlled routinely with
external control samples, and precision was calculated
from the quality-control samples. In general, the
inter-assay coefficients of variation were less than
10%. The methods were linear in the concentration
ranges concerned.
Statistics
Four genes, CRHR1, NPY, SRD5A2 and AKR1C4 were
expressed in less than 50% of the samples, evenly distrib-
uted between groups, and were excluded from further
analyses. Extreme outliers (> 4.9 SD) were removed from
the dataset (n = 16 data points).
Demographic data were compared using Chi-square
tests, one-way ANOVA, or Kruskal-Wallis test, with
Tukey HSD or Dunn’s test as post hoc test, respect-
ively. Testing for normal distribution was done by the
Shapiro-Wilk test. While the majority of ΔCt values
were normally distributed, some were skewed; thus,
data is presented as medians with interquartile ranges
(IQRs). Statistical comparisons between groups were
performed by one-way ANOVA or the Kruskal–Wallis
test, depending on the distribution of the individual
variable. When the results of ANOVA were signifi-
cant, post hoc tests were pursued with the Tukey
HSD test for normally distributed variables and the
Dunn’s test for skewed variables. In addition, correc-
tion for multiple testing was performed according to
Bonferroni. Protein expression was compared between
groups by the Kruskal–Wallis test, followed by
Dunn’s test, and protein expression data is pre-
sented as medians (IQR). Correlation between placen-
tal gene and protein expression was done by
Spearman correlation. Statistical analyses were per-
formed using IBM SPSS software (versions 24.0 and




Demographic and clinical variables of the study groups
are given in Table 1. The three study groups did not dif-
fer in terms of age and BMI, but women with untreated
depression more often continued smoking during preg-
nancy, and women on antidepressant treatment more
often had previous children in comparison with the
healthy controls. In addition, women on antidepressant
treatment had a shorter gestational length at delivery
than those in the other two study groups.
Women with untreated depression had higher scores
of self-rated depression (EPDS) at gestational weeks 17
and 32 in comparison with the controls (Table 1). A
similar pattern was noted in women on antidepressant
treatment, although their self-rated depression scores at
the same time points were lower than among the un-
treated depressed women (p = 0.009 and p = 0.002,
respectively).
The 45 women on antidepressant treatment were most
often using sertraline (n = 17), followed by fluoxetine
(n = 13), citalopram (n = 13) and escitalopram (n = 2).
According to the medical records, 39 (86.7%) had been
using antidepressant treatment throughout pregnancy,
two women during the first half of pregnancy and four
women during the second half of pregnancy. Blood sam-
ples at parturition were available in 41 cases. Of these,
28 showed detectable concentrations of antidepressant
drugs (Table 2).
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Placental gene expression
Overall, following correction for multiple testing, none
of the examined genes were differentially expressed be-
tween healthy controls, women with untreated depres-
sion and women on antidepressant treatment (Table 3).
Nominally significant findings, i.e. not corrected for
multiple comparisons, were noted for HTR1A (5-hy-
droxytryptamine (5-HT)/serotonin receptor 1A), NGF
and NPY2R (neuropeptide Y2 receptor) (Table 3).
These findings remained for HTR1A and NPY2R when
analyses were restricted to women with detectable
serum concentrations of antidepressant drugs at
delivery (median ΔCt for HTR1A of 9.1 (IQR 7.9–11.8),
p = 0.043 and median ΔCt for NPY2R of 10.6 (IQR 8.4–
12.4), p = 0.019). Post hoc analyses revealed that women
with untreated depression had higher gene expression
of HTR1A, (p = 0.039) and NPY2R (p = 0.025) than
healthy controls, whereas women on antidepressant
treatment had similar expression levels of HTR1A and
NPY2R as healthy controls (Fig. 1). No differences in
serotonin (SLC6A4) or noradrenaline (SLC6A2) trans-
porters or in any of the enzymes associated with sero-
tonin synthesis or degradation (tryptophan hydroxylase
1 (TPH1), and 2 (TPH2), AADC, catechol-O-
methyltransferase (COMT) and MAOA)) were noted
between the groups. Further, post hoc analyses revealed
that placental gene expression of NGF was higher in
women with antidepressant treatment than in healthy
controls (p = 0.038; Fig. 1). The placental NGF gene ex-
pression was higher, but not statistically significant,
when restricting the analysis to women with detectable
levels of antidepressant drugs at delivery (median ΔCt
for NGF of 8.3 (IQR 7.8–8.9), p = 0.056).
Further analyses were conducted within the group of
women on antidepressant treatment, comparing those
with and without detectable serum concentrations. With
the exception of CYP3A4, which showed greater expres-
sion in women with detectable serum concentrations of
antidepressants (ΔCt 10.5 (IQR 7.6–11.7) vs. ΔCt 12.5
(IQR 11.1–13.1), p = 0.010), no differentially expressed























Age, years 30.3 ± 3.5 30.3 ± 4.9 31.2 ± 4.8 0.560
BMI, kg/m2 25.7 ± 4.7 25.0 ± 4.4 26.7 ± 5.0 0.339
Nordic origin, n (%) 46 (97.9) 23 (92.0) 42 (93.3) 0.302
University education, n (%) 34 (82.9) 16 (64.0) 28 (70.0) 0.489
Parous, n (%) 19 (40.4) 14 (56.0) 30 (66.7) 0.040 0.207 0.012 0.378
Smoking during pregnancy, n (%) 0 3 (12.0) 1 (2.2) 0.024 0.039 0.489 0.127
Mode of delivery 0.460
Vaginal, n (%) 40 (85.1) 21 (84.0) 34 (75.6)
Planned CS, n (%) 2 (4.3) 2 (8.0) 7 (15.6)
Emergency CS, n (%) 5 (10.6) 2 (8.0) 4 (8.9)
Gestational length, days 282 ± 7 282 ± 8 276 ± 9 0.001 0.995 0.001 0.007
Birthweight, grams 3697 ± 587 3769 ± 427 3640 ± 437 0.571
EPDS in gestational week 17 2 (1–5) 13 (11–16) 7 (5–11) 0.001 0.001 0.001 0.009
EPDS in gestational week 32 3 (1.5–5) 15 (13–16) 7 (5–12) 0.001 0.001 0.001 0.002
Data presented as mean ± SD, median (IQR) or n (%). Statistics by Chi-square tests*, one-way ANOVA*, or Kruskal-Wallis test*. Post hoc tests by Tukey HSD or
Dunn’s test. Frequencies given in relation to available responses. BMI Body Mass Index, CS Caesarean Section, EPDS Edinburgh Postnatal Depression Scale, SD
standard deviation, IQR interquartile range
Table 2 Maternal serum concentrations of antidepressant drugs at parturition in 41 women from whom blood samples were
available




Sertraline 15 8 41.1 ± 71.0 8–216
Fluoxetinea 12 11 420 ± 242 36–739
Citalopram 12 9 102 ± 55 21–208
Escitalopram 2 0 – –
aIncluding its active metabolite norfluoxetine
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Women with untreated depression
(n 25)
Women on antidepressant treatment
(n 45)
Gene n Median (IQR) n Median (IQR) n Median (IQR) p p bonferroni
NPY2R 40 12.3 (10.1–13.3) 20 9.7 (9.1–11.7) 37 10.9 (9.3–12.6) 0.024 0.960
NGF 47 8.8 (8.1–9.5) 25 8.4 (8.3–8.9) 45 8.3 (7.8–9.0) 0.049 1.984
HTR1A 34 10.8 (9.6–12.3) 21 9.0 (7.7–11.3) 27 10.4 (8.8–11.7) 0.049 1.988
OXTR 47 9.5 (8.4–11.1) 25 9.3 (7.4–10.0) 45 8.9 (7.9–10.3) 0.081
BDNF 47 6.3 (5.9–6.8) 25 6.0 (5.2–6.4) 45 6.4 (5.8–6.7) 0.091
CRH 47 0.7 (−0.2–2.3) 24 0.1 (−1.0–1.1) 45 1.0 (− 0.1–2.1) 0.102
NR3C1 47 3.0 (2.6–3.4) 25 2.8 (2.0–3.0) 45 2.8 (2.3–3.2) 0.133
MAOA 47 1.0 (0.7–1.6) 25 0.7 (0.3–1.1) 45 1.1 (0.6–1.5) 0.153
TPH1 46 11.7 (10.7–12.7) 24 12.2 (11.3–12.7) 44 11.6 (10.8–12.3) 0.189
RAF-1 47 5.1 (4.7–5.4) 25 4.8 (4.5–5.2) 45 5.0 (4.7–5.3) 0.193
HTR3E 47 9.9 (8.9–10.8) 24 9.1 (8.7–10.4) 45 9.9 (8.7–10.8) 0.195
ROCK2 47 3.0 (2.7–3.3) 25 2.9 (2.5–3.1) 44 2.9 (2.5–3.3) 0.204
AADC 33 11.4 (10.0–12.3) 19 11.5 (8.8–13.9) 30 10.8 (8.8–11.9) 0.206
OXT 32 12.9 (11.4–14.0) 18 12.4 (11.1–12.7) 25 12.6 (11.5–13.2) 0.280
SRD5A1 47 9.2 (8.8–9.6) 25 9.0 (8.6–9.4) 45 9.2 (8.7–9.6) 0.301
ROCK1 46 4.1 (3.8–4.4) 25 3.8 (3.7–4.2) 45 3.8 (3.5–4.1) 0.313
COMT 45 2.9 (2.2–3.2) 25 3.1 (2.8–3.3) 43 2.9 (2.5–3.4) 0.318
TPH2 46 10.4 (9.3–12.2) 25 11.1 (10.4–11.7) 44 11.3 (10.2–12.1) 0.356
HSD11B1 47 5.6 (4.8–6.4) 25 5.8 (4.2–6.3) 45 5.9 (5.2–6.4) 0.426
CYP3A4 26 12.0 (9.5–13.5) 14 11.3 (9.9–12.7) 19 11.1 (8.6–12.5) 0.456
CYP2D6 47 8.7 (7.9–9.7) 25 8.7 (7.6–9.1) 45 8.8 (8.0–9.4) 0.478
GABRG2 43 9.9 (8.9–10.7) 23 10.3 (9.0–11.8) 42 9.7 (8.7–11.3) 0.478
CYP1A2 25 11.7 (10.7–14.1) 19 10.9 (9.8–12.1) 29 11.4 (9.6–13.1) 0.506
PTGDS 47 2.0 (1.5–2.7) 25 1.9 (1.1–2.6) 45 1.9 (1.0–2.6) 0.539
HSD11B2 47 2.5 (1.7–3.3) 24 1.9 (1.6–2.6) 45 2.0 (1.4–3.1) 0.573
SLC6A2 47 3.6 (3.1–4.4) 25 3.5 (3.1–4.2) 45 3.7 (3.5–4.3) 0.624
SLC6A4 46 3.7 (3.3–4.1) 24 3.8 (3.5–4.1) 45 3.8 (3.4–4.4) 0.669
CDH2 47 10.1 (8.3–11.8) 25 10.0 (8.8–11.8) 44 9.4 (8.5–11.0) 0.685
NTRK1 37 10.1 (7.5–11.8) 18 9.0 (7.3–11.4) 31 9.5 (8.0–10.7) 0.724
ALAD 47 4.6 (4.4–4.9) 25 4.6 (4.3–4.9) 45 4.6 (4.3–5.0) 0.726
NPY1R 47 9.6 (9.0–10.0) 25 9.6 (8.7–10.0) 45 9.6 (8.5–10.5) 0.769
CREB1 47 4.2 (3.7–4.4) 25 3.9 (3.7–4.4) 45 4.0 (3.7–4.4) 0.824
CRHBP 47 6.5 (5.4–7.6) 25 6.4 (5.3–8.0) 45 6.7 (5.5–8.1) 0.851
ABCB1 47 5.3 (4.1–5.8) 25 4.8 (4.1–5.9) 45 5.1 (4.1–6.7) 0.855
VEGFA 47 4.6 (3.6–5.4) 25 4.5 (3.6–5.4) 45 4.4 (3.6–5.0) 0.860
HTR7 46 10.1 (9.1–11.6) 25 10.2 (9.2–10.9) 45 10.1 (8.9–10.8) 0.879
PGF 47 0.1 (−1.0–0.7) 25 −0.1 (−1.0–0.9) 45 −0.1 (− 0.6–0.3) 0.893
CCK 46 10.4 (8.4–11.3) 24 10.2 (8.2–11.3) 45 9.4 (8.1–11.4) 0.923
NTRK2 47 9.2 (8.2–9.9) 24 9.1 (8.6–9.9) 44 9.0 (8.4–9.8) 0.956
VIP 46 10.1 (9.2–10.9) 25 9.8 (9.4–10.5) 45 9.9 (9.4–10.6) 0.971
Data presented as median ΔCt (IQR). Statistical tests by one-way ANOVA or Kruskal Wallis test, depending on normal distribution. Genes sorted according to the
degree of statistical significance
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placental genes were detected between these two groups
(data not shown).
Placental protein expression
Genes nominally significantly different between groups
were selected for placental protein expression determin-
ation. NGF was not included in the protein analyses, as
this has previously been reported by our group [29].
Immunohistochemical staining of HTR1A showed
medium-strong intensity in placental trophoblasts and
endothelial cells, and medium intensity in stromal cells,
whereas staining of NPY2R displayed medium intensity
in trophoblasts and weak intensity in endothelial and
stromal cells (Fig. 2). HTR1A staining intensity in tro-
phoblasts differed between groups (Table 4), and the dif-
ference remained significant in analyses restricted to the
treated women with detectable antidepressant serum
levels, compared with healthy controls and untreated de-
pressed women (p = 0.043). The highest level of HTR1A
expression was noted in women on antidepressant treat-
ment, in comparison with healthy controls (p = 0.031;
Fig. 3). No difference in endothelial and stromal-cell
expression of HTR1A was noted between groups. No
correlation between placental gene and protein expres-
sion of HTR1A was noted (trophoblasts, rho = 0.004,
p = 0.98; endothelial cells, rho = − 0.18, p = 0.27; stromal
cells, rho = − 0.06, p = 0.71).
No difference between groups in placental NPY2R
protein expression was confirmed. Gene expression of
NPY2R was negatively correlated with corresponding
protein expression in placental endothelial and stromal
cells (trophoblasts, rho = − 0.11, p = 0.43; endothelial
cells, rho = − 0.35, p = 0.009; stromal cells, rho = − 0.30,
p = 0.025).
Discussion
Following correction for multiple testing, our study did
not reveal any significant differences in placental gene
expression, of the 44 tested genes, between women with
antenatal depression, women with antidepressant treat-
ment, and healthy controls. However, given the preg-
nancy outcomes at stake, i.e. placental function and
consequent fetal well-being, it can be argued that a sta-
tistically correct approach may conceal clinically rele-
vant findings. For this reason, we have also reported on
the few nominally significant transcripts that were de-
tected primarily in women with antenatal depression.
All in all, the enhanced gene expression of HTR1A in
placentas from women with untreated depression, to-
gether with the stronger immunohistochemical staining
of HTR1A in the treatment group, could strengthen the
theory of the involvement of HTR1A in maternal de-
pression and placental function. HTR1A has previously
been identified in placental tissue [54]. Serotonin recep-
tors in the placenta are important for maintenance of
the normal development of the fetal brain [55, 56]. Al-
terations in the placental expression of serotonin recep-
tors have been associated with maternal stress [56] and
infant neurodevelopment [57]. While HTR1A has previ-
ously been described in the trophoblasts of human pla-
centa, at present no information on the role of this
receptor in placental function has been published. Not-
ably, the observed differences in placental HTR1A gene
and protein expression were not accompanied by
changes in the serotonin or noradrenaline transporters
or in any of the enzymes associated with serotonin syn-
thesis or degradation in our study cohort, at least at
gene-expression level.
5-HT1A receptors can be found as both heterorecep-
tors and autoreceptors [58–60]. Upon binding of the
neurotransmitter to the autoreceptor, a negative feed-
back loop inhibits further release of the neurotransmitter
[61]. Prolonged administration of SSRIs will decrease the
autoreceptors’ sensitivity for neurotransmitters, leading
to an elevated concentration of synaptic serotonin [61,
62]. While presynaptic 5-HT1A autoreceptors may delay
the effect of antidepressant treatment, the stimulation of
postsynaptic 5-HT1A receptors in corticolimbic networks
Fig. 1 Placental gene expression (median ΔCt, IQR) in women with antenatal depression (n = 25), antidepressant treatment (n = 45), and healthy
controls (n = 47). Women with untreated depression had higher gene expression of HTR1A, p = 0.039 (Tukey HSD), and NPY2R, p = 0.025 (Dunn’s
test), than healthy controls. The gene expression of NGF was higher in women with antidepressant treatment than in healthy controls, p = 0.038
(Tukey HSD)
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is beneficial for antidepressant action [63]. Moreover,
polymorphisms in the gene encoding 5-HT1A [64, 65],
and altered regulation of 5-HT1A [66] have been associ-
ated with depression. A study by Olivier et al. has re-
vealed increased 5-HT1A receptor sensitivity in
prenatally fluoxetine-exposed rats, which may, in part,
explain the neurodevelopmental changes observed in
these animals [67].
In this study, NGF gene expression was higher in pla-
cental tissue from women using antidepressants during
pregnancy. This finding is in line with previous data,
where we showed that NGF protein expression was in-
creased in both trophoblasts and endothelial cells from
women using antidepressants during pregnancy com-
pared with NGF protein expression in placentas from
depressed and healthy controls [29]. Together, these
Fig. 2 Immunohistochemically stained placental tissue from representative women with antenatal depression, antidepressant treatment, and
healthy controls. Antibodies: anti-HTR1A (PA5–28090, rabbit, Thermo Fisher Scientific, dilution 1:500), anti-NPY2R (PA1–41576, rabbit, Thermo
Fisher Scientific, dilution 1:250). Scale bar = 200 μm. Objective 20x




Women with untreated depression
(n 13)




Trophoblasts 238 (206–263) 225 (213–244) 263 (238–288) 0.017
Endothelial cells 225 (175–238) 225 (169–263) 225 (206–263) 0.284
Stroma cells 175 (138–213) 175 (156–194) 175 (175–231) 0.258
NPY2R
Trophoblasts 188 (156–213) 213 (163–225) 200 (163–238) 0.743
Endothelial cells 63 (50–63) 63 (50–113) 50 (50–81) 0.351
Stroma cells 50 (50–63) 63 (50–113) 50 (50–81) 0.370
Data presented as median H-score (IQR). Statistics by Kruskal-Wallis test
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results indicate that SSRI use during pregnancy may
affect NGF signalling in the placenta.
The neuropeptide Y2 receptor (NPY2R), which ex-
hibited enhanced gene expression in untreated de-
pressed women, is known to have appetite-inhibiting
properties [68, 69]. In addition to food intake, mem-
bers of the NPY family exert effects on psychomotor
activity, regulation of endocrine secretion, energy
homeostasis, and effects on the cardiovascular system
[68]. There are also studies showing increased levels
of NPY in pre-eclamptic women, suggesting involve-
ment in placental function [70]. NPY has been identi-
fied in the brain and placenta in rats [71]. Members
of the NPY family have also been implicated in CNS
functions in primates, where, for example, activation
of NPY2R is thought to exert anxiogenic actions [72].
Our results, however, revealed unchanged protein ex-
pression in the placenta in relation to the exposures
involved. Thus, this finding needs replication before
any meaningful interpretations can be made.
The major strengths of this study include the sample
of placentas from obstetrically healthy women with
stringent definition of antenatal depression, and women
on antidepressant treatment. Further, the use of SSRIs is
validated by serum concentrations of the actual drug in
question. Additional strengths are age- and BMI-
matched controls, and validation of the gene-expression
results at a protein level by immunohistochemistry. Even
so, some limitations need to be mentioned. The use of
human placentas inevitably introduces great variability,
in this study seen in the various types, doses and dur-
ation of antidepressant treatment. Similarly, the severity
and duration of antenatal depression also differed be-
tween women. This heterogeneity may influence and po-
tentially dilute important findings, but on the other
hand, restriction to more stringent samples would affect
power in individual analyses. Another limitation is the
lower number of samples available for protein analysis
compared with those available for gene expression ana-
lysis (71 out of 117). Only 28 of 41 women had detect-
able serum concentrations of an antidepressant drug at
delivery. While the serum concentrations validate the
medical reports of ongoing SSRI use, it should be
stressed that non-confirmation of SSRI treatment in
serum does not necessarily mean the placenta has not
been exposed to treatment during pregnancy. Many
women are aware of neonatal complications from SSRI
use during late pregnancy [73], and some discontinue in
preparation for delivery to avoid such problems [74, 75].
Clearly, no difference in results was noted when analyses
were restricted to women with confirmed SSRI use, and
there were also no differences in placental gene expres-
sion between women with detectable and non-detectable
antidepressant serum concentrations.
Investigators have described associations between poor
mental health, impaired placental function, and poor
pregnancy outcomes such as preterm birth and low birth
weight [13–15], but the underlying biological mecha-
nisms are not fully understood. More research is re-
quired to elucidate the causal relationships between
these factors. Our findings may be interpreted as being
both reassuring and worrying for women who suffer
from antenatal depression and need treatment for their
condition. The genes investigated were primarily chosen
because they have been linked to depression in various
human and animal studies. Thus, at the gene level, it
may not be surprising that the findings of interest were
noted only among women with antenatal depression,
whereas SSRI users had similar gene-expression levels as
the healthy controls. While this finding may appear re-
assuring, potentially suggesting that treatment of ante-
natal depression normalizes placental gene expression, it
is contradicted by the findings at the protein level. If we
had chosen genes on the basis of their association with
antidepressant use, we might have revealed a different
picture. Further reassuring findings were that some of
Fig. 3 Protein expression (median H-score, IQR) in placental trophoblasts in women with antenatal depression (n = 13), antidepressant treatment
(n = 21), and healthy controls (n = 37). The highest HTR1A expression was noted in women on antidepressant treatment, in comparison with
healthy controls, p = 0.031 (Dunn’s test). No difference between groups in placental NPY2R protein expression was confirmed
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the genes we studied are known to have an impact on
long-term fetal health, such as HSD11B1 and 2, which
control the shuttling of cortisol to the fetus. While ma-
ternal stress is known to affect this placental enzyme
[35–37, 39], we found no evidence that antenatal depres-
sion or antidepressant treatment had such effects. Not-
ably, however, gene expression does not equal function,
and previous studies from our group have demonstrated
that the maternal cortisone:cortisol ratio, as a functional
measure of this enzyme, is positively associated with
birth weight in women with psychiatric disease [76]. Of
concern, this study has demonstrated differential expres-
sion of serotonin receptor 1A and NPY2 receptor, both
of which currently are of unclear relevance as regards
placental function. Previous microarray studies have
demonstrated a multitude of genes that are differentially
expressed, especially in women on antidepressant treat-
ment [30], and absence of findings in our study should
not be interpreted as the full picture, or that SSRI use
during pregnancy is without harm. Clearly, further stud-
ies in this area are needed, and the review by Gentile
and Fusco describes the importance in more rigorous
assessments including ultrasound studies on fetal re-
sponses to maternal mood and antidepressant medica-
tion and also analyses of epigenetic modifications
associated with antenatal depression and antidepressant
treatment [28].
Conclusion
The differential expression of HTR1A at both the gene
and protein level that was revealed in this study suggests
the involvement of HTR1A in the effect of antenatal de-
pression on biological mechanisms in the placenta. More
research is needed to elucidate the roles of depression
and antidepressant treatment on placental gene and
protein expression, especially as regards HTR1A, and,
further, the effect on the fetus.
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